Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer

Altundag Kadri

首页> 外文期刊>The breast journal >Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer

【24h】

Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer

机译：较高的预处理和芳香酶抑制剂治疗相关的心血管疾病在绝经后激素受体阳性患者早期乳腺癌患者的风险

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The breast journal》 |2017年第3期|共1页
作者
Altundag Kadri;
展开▼
作者单位

Hacettepe Univ Canc Inst Dept Oncol TR-06100 Ankara Turkey;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类乳房;
关键词

相似文献

外文文献
中文文献
专利

1. Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer [J] . Altundag Kadri The breast journal . 2017,第3期

机译：较高的预处理和芳香酶抑制剂治疗相关的心血管疾病在绝经后激素受体阳性患者早期乳腺癌患者的风险
2. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting [J] . Pedro Sánchez-Rovira, Angelica Lindén Hirschberg, Miguel Gil-Gil, The oncologist . 2020,第12期

机译：II期预期，随机，双盲，安慰剂控制和多中心临床试验，以评估早期乳腺癌的激素受体阳性绝经后妇女0.005％雌激素阴道凝胶的安全性与佐剂酶抑制剂治疗
3. A phase II prospective, randomized, double-blind, placebo-controlled multi-centre clinical trial to assess the safety of 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting - Initial safety results [J] . Sanchez Rovira P., Gil Gil M., Presa Lorita J., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Suppla2期

机译：一项II期前瞻性，随机，双盲，安慰剂对照的多中心临床试验，用于评估0.005％雌三醇阴道凝胶剂对激素受体阳性的绝经后早期乳腺癌女性进行芳香化酶抑制剂（AI）治疗的安全性。辅助设定-初步安全结果
4. Bone Density Changes during Adjuvant Aromatase Inhibitor Treatment in Breast Cancer Patients: Single Centre Experience [C] . World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：乳腺癌患者辅助芳香化酶抑制剂治疗期间的骨密度变化：单中心经验。
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index [O] . M A N Sendur, S Aksoy, N Zengin, 2012

机译：体重指数对激素受体阳性绝经后乳腺癌患者辅助芳香化酶抑制剂的疗效
7. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index [O] . M A N Sendur, S Aksoy, N Zengin, 2012

机译：佐剂芳族酶抑制剂在血管酮受体阳性绝经后乳腺癌患者的疗效根据体重指数

Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer

著录项

相似文献

相关主题

期刊订阅